J&J takes Shire bid for Movetis stake; Genzyme stirs interest in for-sale units;

 @FiercePharma: Did FDA know about J&J's 'phantom' recall? Article | Follow @FiercePharma

> Shire's 428 million-euro ($569 million) takeover of Belgian drugmaker Movetis moved a step closer after founding shareholder Johnson & Johnson (JNJ.N) accepted the U.K. firm's cash offer for its 13 percent stake. Article

> Genzyme, a takeover target of Sanofi-Aventis, expects to complete sales of its diagnostics and pharmaceutical-ingredients units by the end of the year, with six bidders already in hand for the drug business. Report

> Four Republican senators have written a letter to their party leaders saying they intend to block a recently passed Senate spending bill because the legislation contains a provision that would ban pay-for-delay deals between brand-name and generic drugmakers. Story

> Sanofi-Aventis may unveil "at least another couple critical partnerships" in diabetes in the months to come, Riccardo Perfetti, senior medical director for the drugmaker's diabetes unit, tells Bloomberg. News

> Scientists ID molecule that could predict Type 2 diabetes. News

> Workers at pharmaceutical firm AstraZeneca's site in Macclesfield will strike for the third time in a month tomorrow over a row about pensions. Item

> Shares in Sun Pharmaceutical Industries rallied to an all-time high after the Indian drugmaker completed its buyout of a controlling stake in Taro Pharmaceutical Industries. Report

> New biomarker panel flags risk of preeclampsia. Article

> Generic drugmaker Mylan obtained a federal court order blocking a competing version of its antidepressant Paxil from the U.S. market. Mylan release | Story

> Mt. Sinai researchers tout new approach to biomarkers. Story

> Teva Pharmaceutical Industries hsa sued Mylan for patent infringement, escalating a fight between the rival drugmakers over the top-selling Copaxone multiple sclerosis treatment. Teva release | Story

Biotech News

@FierceBiotech: Boehringer gets unanimous support for blockbuster stroke drug. News  | Follow @FierceBiotech

 @JohnCFierce: Abbott cuts include Solvay's Marietta, GA pharmaceuticals ops. Article | Follow @JohnCFierce

> Novartis wins landmark approval for oral MS drug. News

> GSK, Theravance report promising PhII data for Advair successor. Article

> Lundbeck cuts R&D staff in shift to new collaborations. Report

> Sanofi's critical limb ischemia drug flunks PhIII. Story

Drug Delivery News

> Emisphere technology delivers anti-hunger hormones. Article

> Elan distances itself from delivery. Report

> Savara gains $1.4M for pulmonary NanoCluster delivery. News

Medical Devices

> Sen. Franken, Hamburg discuss device industry's concerns. Story

> 3D printing could benefit med device making. Report

> Boston Sci purchases Asthmatx for $443.5M. Article

> Medtronic gets FDA approval for Integrity coronary stent. News

And Finally... Modern antipsychotic drugs, especially AstraZeneca's blockbuster Seroquel, may increase the risk of patients developing life-threatening blood clots, British researchers said. Report

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.